The Dimension Study is a planned clinical phase III trial, set to commence in Europe in 2025. This extensive study, led by a consortium comprising MIND, SPRIN-D (the German Federal Agency for Disruptive Innovation), Usona, and the Central Institute for Mental Health (ZI Mannheim), will be the largest psychedelic trial ever conducted, with over 700 patients receiving a combination treatment of psilocybin and psychotherapy over a span of 32 weeks. The trial is currently in the preparation phase and will be funded equally by public sources and philanthropic contributions.

The core of the Dimension Study is its Health Technology Assessment (HTA) and approval study, which aims to evaluate the efficacy of psilocybin plus psychotherapy (PAP) compared to the standard treatment of antidepressants plus psychotherapy. By doing so, the study seeks to bring psilocybin into the public reimbursement system, potentially revolutionizing mental health treatment by providing a novel therapeutic option.

Join us in this pioneering effort to transform the landscape of mental health care.

The EPIsoDE study, in which the MIND Foundation participated as a junior partner, has recently been completed. This phase-2b clinical study, led by the Central Institute for Mental Health (ZI) Mannheim and Charité – Universitätsmedizin Berlin, investigated the efficacy and safety of psilocybin in treatment-resistant unipolar depression. During the study, 144 patients received either a high/therapeutic dose, a low dose, or a control substance to evaluate the antidepressant effects of psilocybin. EPIsoDE is the largest publicly funded and clinical trial with psilocybin to date.

The main goal of the EPIsoDE study was to determine whether psilocybin has a better antidepressant effect than a placebo and to identify the most effective dosage. Initial results from other studies suggest that psilocybin, when used in a psychotherapeutic context, could be promising, particularly for patients for whom other treatments have failed. 

The MIND Foundation is proud to have been part of this significant step in psychedelic research and remains committed to contributing to the exploration and application of innovative therapies.

From February to December 2023, this research project funded by the German Federal Ministry of Education and Research (BMBF) explored the knowledge and attitudes towards psychedelic therapies among various stakeholders, including medical professionals, patients, health insurers, politicians, and the public. As the approval of psilocybin and MDMA for therapeutic use within the healthcare system is anticipated in the coming years, this study gathered insights to shape the societal implementation of these treatments, maximizing their potential while minimizing risks.

The study employed two main research methods: an anonymized online questionnaire and focus group interviews. The online survey invited participants to share their views on psilocybin as a new treatment in medicine and psychotherapy. Additionally, focus group interviews were conducted both at the MIND Foundation and online, providing a platform for in-depth discussions about existing opinions, concerns, and potential obstacles to the implementation of psilocybin-assisted therapy.

The OVID Clinic Berlin stands out as the only non-university institution in Germany serving as a study center for clinical trials involving psychedelic substances on the path to drug approval. Under the leadership of Dr. med. Andrea Jungaberle and Dr. med. Marc Bos, the clinic is participating in two groundbreaking clinical studies focused on the efficacy of psychedelic substances in treating depression (5-MeO-DMT) and generalized anxiety disorder (LSD derivative). These studies have received approval from the BfArM and relevant ethics committees.

Discover ongoing MIND surveys, an overview of completed survey studies, and surveys currently being conducted by our global partners. Here is an overview of completed surveys, links to ongoing, as well as featured partner surveys.

Participate!

We encourage you to take part in our surveys and share them within your networks to help us recruit more respondents. Your participation is invaluable in advancing psychedelic research.

Have you ever had an experience with psychedelics that you found particularly challenging or traumatic? If so, we would be delighted if you would take part in the following online survey, which is being conducted at the Institute of Psychology at Humboldt-Universität zu Berlin.

The Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ) is a psychometric self-report tool for measuring aspects of the acute psychedelic experience that are associated with longer-term changes in psychological flexibility.

English and German versions of the 32-item APEQ and the 12-item short form APEQ-S were validated with the data collected in the Psychedelic Experience Survey. 

A Spanish translation of the APEQ is currently being validated.

Find the publication and questionnaire below:

The General Change Mechanisms Questionnaire (GCMQ) is a tool to study mechanisms of change in psychedelic therapy.

Please find the publication of the validated GCMQ below: